Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cell & Gene Therapy Asia 2019

Toshiyoshi Fujiwara's Biography

Toshiyoshi Fujiwara, Professor & Chairman, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Dr. Fujiwara is a gastrointestinal surgeon and a clinical investigator at Okayama University Graduate School. He serves as the Vice Director of Okayama University Hospital and also holds an appointment as the Director of the Minimally Invasive Therapy (MIT) Center. His research interest is the molecular diagnostic and therapeutics for gastrointestinal neoplasms. He has completed the first tumor suppressor gene therapy trial in Japan. He is currently developing telomerase-specific oncolytic adenoviruses for the diagnostic and therapeutic application. He is a Boards of Directors of the Japan Surgical Society and the Japan Society of Gene and Cell Therapy.

Toshiyoshi Fujiwara Image

Multidisciplinary Oncolytic Virotherapy for Gastrointestinal Cancer

Tuesday, 12 November 2019 at 12:50

Add to Calendar ▼2019-11-12 12:50:002019-11-12 13:50:00Europe/LondonMultidisciplinary Oncolytic Virotherapy for Gastrointestinal CancerCell and Gene Therapy Asia 2019 in Kobe, JapanKobe,

Telomelysin (OBP-301) is an attenuated oncolytic adenovirus, in which the telomerase promoter drives expression of E1 genes. Telomelysin causes selective replication and lysis of a variety of human cancer cells, and also inhibits the repair of radiation-induced DNA double-strand breaks, leading to radiosensitization. A phase I study has confirmed the safety and biological activity of Telomelysin alone in patients with advanced solid tumors in the US. To further determine the feasibility, efficacy, and pharmacokinetics of Telomelysin in combination with radiotherapy, an investigator-driven clinical study was designed. Patients with histologically confirmed esophageal cancer who were not eligible for surgery or chemotherapy were enrolled into this study. Study treatment consisted of intratumoral needle injections of Telomelysin on days 1, 18, and 32 of treatment. Radiation therapy was administered concurrently over 6 weeks, beginning on day 4, to a total of up to 60 Gy. Virus administration was performed by intratumoral injection of the primary tumor through a flexible endoscope. Patients receive escalating doses of Telomelysin (1010 to 1012 virus particles [vp]). Seven, three, and three patients were enrolled and treated in the cohorts with 1010, 1011, and 1012 vp of Telomelysin, respectively. The patients comprised 10 males and 3 females, with median age of 79.7 years (range, 53 to 92 years). Common grade 1 and 2 toxicities included fever, esophagitis, pneumonitis, anorexia, constipation, and gastroesophageal reflux disease. All patients developed a transient, self-limited lymphopenia. Objective responses were complete response (CR) in 4, 2, and 2 patients in cohort 1, 2, and 3, respectively; all of them exhibited pathologically no viable malignant cells in biopsy specimens. Histopathologic examination in post-treatment specimens showed massive infiltration of CD8+ cells in 3 partially responded tumors. Multiple courses of endoscopic Telomelysin injection with radiotherapy were feasible and well tolerated in patients with esophageal cancer, and appeared to provide clinical benefit.

Add to Calendar ▼2019-11-11 00:00:002019-11-12 00:00:00Europe/LondonCell and Gene Therapy Asia 2019Cell and Gene Therapy Asia 2019 in Kobe, JapanKobe,